含呋喃唑酮的四联疗法补救根除幽门螺杆菌疗效的Meta分析

摘要

目的：通过Meta分析研究含呋喃唑酮的四联疗法补救根除幽门螺杆菌（ Hp）的疗效及安全性。方法检索中国知网、中国生物医学文献数据库、维普中文科技期刊数据库、万方数据库、PubMed、EMBase，收集含呋喃唑酮的四联疗法与常规四联疗法对比补救根除Hp疗效的国内随机对照试验，检索日期截止2015年1月，采用Cochrane协作网提供的RevMan5．0软件进行Meta分析。结果纳入6个研究，共788例患者，其含呋喃唑酮的治疗组396例，常规疗法的对照组392例。 Meta分析结果显示，含呋喃唑酮四联疗法的治疗组的Hp根除率明显高于对照组（P＜0．05），两组不良反应发生率比较，差异无统计学意义（P＞0．05）。结论与常规四联疗法相比，含呋喃唑酮的四联疗法补救根除Hp的疗效更好，不良反应发生率无差异。%Objective To study the efficacy and safety of furazolidone-containing quadruple remedial therapy for Helicobacter pylori (Hp) eradication by using Meta-analysis.Methods CNKI,CBM Database,VIP Database,Wangfang Database,PubMed and EMBase were searched for the domestic randomized controlled trials( RCTs) concerning furazolidone-containing or routine quadruple remedial therapy for Hp eradication,setting a deadline of January 2015.RevMan 5.0 software which was supported by the Cochrane Collaboration was used to conduct a Meta-analysis.Results Six trials involving 788 patients were included,396 receiving furazolidone-containing therapy in the case group and 392 receiving conventional therapy in the control group.The result of the Meta-analysis showed that case group receiving furazolidone-containing quadruple therapy gained a significantly higher rate of Hp eradication compared with control group(P<0.05),there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion The furazolidone-containing quadruple remedial therapy for Hp eradication achieves better effects compared with the conventional quadruple therapy,but there is no significant difference in the incidence of adverse reactions between the two therapies.